CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Texas Southwestern Medical Center
About this trial
The study will be conducted at the following locations:
1. UT Southwestern Medical Center 2. Parkland Health and Hospital System 3. University of Michigan
Investigators will prospectively compare the performance of dynamic contrast enhanced abbreviated MRI (AMRI) and contrast-enhanced ultrasound for early-stage HCC detection in patients with indeterminate liver nodules.
Eligibility criteria
Qualifiers
Child A or B cirrhosis from any etiology with at least one ILN on 4-phase CT, contrast- enhanced MRI, or contrast enhanced US but without HCC at baseline.
Adults 18 years old and above
Disqualifiers
Patients post liver transplantation
Patients with concurrent or prior HCC (LR-5 or biopsy proven)
other liver cancer including cholangiocarcinoma
Patients with any active extra-hepatic malignancy
Trial design
Treatments tested in this trial
- CEUS imaging
- aMRI imaging
Treatment groups
600 Participants
are divided into 1 treatment groupLocations
2University of Michigan48109, Ann ArborMichigan, United States
University of Texas Southwestern Medical Center75390, DallasTexas, United States
Sponsors and collaborators
University of Texas Southwestern Medical Center
Lead sponsor
University of Michigan
Collaborator
Source ClinicalTrials.gov